Browsing ICR Divisions by author "Soosainathan, Arany"
Now showing items 1-2 of 2
-
Identification of novel targets for the treatment of endocrine-resistant breast cancer
Soosainathan, A (Institute of Cancer Research (University Of London), 2022-05-31)While endocrine therapy is an effective, well-tolerated treatment for oestrogen receptor positive (ER-positive) breast cancer, a large proportion of initial responders will develop hormone therapy resistance, and relapse. ... -
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan, A; Iravani, M; El-Botty, R; Alexander, J; Sourd, L; et al. (AMER ASSOC CANCER RESEARCH, 2024-01-02)UNLABELLED: The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor-positive (ER+) breast cancer, yet many patients relapse with ...